CYCN Cyclerion Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CYCN

Price (delayed)

$3.08

Market cap

$13.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$10.51M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates ...

Highlights
The net income has dropped by 79% year-on-year and by 50% since the previous quarter
The quick ratio has plunged by 65% from the previous quarter and by 58% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cyclerion.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CYCN

CYCN stock price

How has the Cyclerion Therapeutics stock price performed over time
Intraday
2.67%
1 week
-3.14%
1 month
-5.52%
1 year
-1.6%
YTD
142.52%
QTD
98.71%

Financial performance

How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$1.99M
Gross profit
$1.99M
Operating income
-$6.73M
Net income
-$5.28M
Gross margin
100%
Net margin
-264.7%
Cyclerion Therapeutics's operating margin has plunged by 103% YoY and by 41% from the previous quarter
The operating income has plunged by 94% YoY and by 35% from the previous quarter
Cyclerion Therapeutics's net margin has plunged by 87% YoY and by 56% from the previous quarter
The net income has dropped by 79% year-on-year and by 50% since the previous quarter

Price vs fundamentals

How does CYCN's price correlate with its fundamentals

Growth

What is Cyclerion Therapeutics's growth rate over time

Valuation

What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
1.96
P/S
6.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.28
Cyclerion Therapeutics's EPS has decreased by 23% from the previous quarter and by 17% YoY
The stock's price to book (P/B) is 112% more than its last 4 quarters average of 0.9 and 36% more than its 5-year quarterly average of 1.4
The equity has contracted by 25% from the previous quarter and by 23% YoY
CYCN's P/S is 111% above its last 4 quarters average of 3.0
The revenue has declined by 4.2% year-on-year and by 3.9% since the previous quarter

Efficiency

How efficient is Cyclerion Therapeutics business performance
Cyclerion Therapeutics's ROS has plunged by 87% YoY and by 56% from the previous quarter
The company's return on equity has shrunk by 83% YoY and by 58% QoQ
CYCN's return on assets has dropped by 79% year-on-year and by 55% since the previous quarter
The return on invested capital has dropped by 78% year-on-year and by 58% since the previous quarter

Dividends

What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYCN.

Financial health

How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total liabilities has soared by 90% from the previous quarter and by 61% YoY
The quick ratio has plunged by 65% from the previous quarter and by 58% YoY
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has contracted by 25% from the previous quarter and by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.